Peply
← All Compounds

Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

Epitalon (Epithalon)

Removed from Cat 2

Longevity & Immune · Research peptide (multiple suppliers)

Synthetic tetrapeptide researched for telomerase activation and pineal gland function. Not FDA-approved for any indication.

About

Mechanism
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) analog of epithalamin that activates telomerase and may support pineal gland function and melatonin production.
Half-Life
Estimated 1-2 hours
Route
subcutaneous
Frequency
Daily in 10-day cycles

Clinical Dosing

5-10 mgdaily in 10-day cycles

Removed from Category 2 by FDA (April 15, 2026). Will be evaluated by PCAC beginning July 2026. Not yet Category 1 — awaiting formal PCAC review.

Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.

Regulatory Status

FDA Category
Research peptide (removed from FDA Category 2)
Reclassification
removed-from-cat2
Date Restricted
2023-09-29
Announced Return
2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Cycling Protocol

Source: Khavinson et al., Bulletin of Experimental Biology and Medicine, 2003

DoseDurationDraw (10 mg vial in 2mL)Notes
10 mg2 weeks2.00 mL (200 units)10-day cycle, then break. Repeat 2-3x/year

Available Vial Sizes

10 mg

10 mg vial

20 mg

20 mg vial

50 mg

50 mg vial

Citations

  1. [1]Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bulletin of Experimental Biology and Medicine, 135(6), 590-592. Link(Reviewed: 2026-04-16)